[1] Nandakumar A, Anantha N, Venugopal TC. Incidence, mortality and survival in cancer of the cervix in Bangalore, India. Br J Cancer 1995;71:1348–52. https://doi.org/10.1038/bjc.1995.262.
[2] Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019;144:1941–53. https://doi.org/10.1002/ijc.31937.
[3] Balasubramaniam G, Sushama S, Rasika B, Mahantshetty U. Hospital-based study of endometrial cancer survival in Mumbai, India. Asian Pac J Cancer Prev 2013;14:977–80. https://doi.org/10.7314/apjcp.2013.14.2.977.
[4] Kirwan JM, Symonds P, Green JA, Tierney J, Collingwood M, Williams CJ. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol 2003;68:217–26. https://doi.org/10.1016/S0167-8140(03)00197-X.
[5] Gandhi AK, Sharma DN, Rath GK, Julka PK, Subramani V, Sharma S, et al. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: A prospective randomized study. Int J Radiat Oncol Biol Phys 2013;87:542–8. https://doi.org/10.1016/j.ijrobp.2013.06.2059.
[6] Chen LA, Kim J, Boucher K, Terakedis B, Williams B, Nickman NA, et al. Toxicity and cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for postoperative treatment of gynecologic cancers. Gynecol Oncol 2015;136:521–8. https://doi.org/10.1016/j.ygyno.2014.12.039.
[7] Mendenhall WM, Amdur RJ, Palta JR. Intensity-modulated radiotherapy in the standard management of head and neck cancer: Promises and pitfalls. J Clin Oncol 2006;24:2618–23. https://doi.org/10.1200/JCO.2005.04.7225.
[8] Mundt AJ, Lujan AE, Rotmensch J, Waggoner SE, Yamada SD, Fleming G, et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002;52:1330–7. https://doi.org/10.1016/S0360-3016(01)02785-7.
[9] Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Yamada SD, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:1356–65. https://doi.org/10.1016/j.ijrobp.2006.03.018.
[10] Small W, Mell LK, Anderson P, Creutzberg C, De Los Santos J, Gaffney D, et al. Consensus Guidelines for Delineation of Clinical Target Volume for Intensity-Modulated Pelvic Radiotherapy in Postoperative Treatment of Endometrial and Cervical Cancer. Int J Radiat Oncol Biol Phys 2008;71:428–34. https://doi.org/10.1016/j.ijrobp.2007.09.042.
[11] Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997;350:535–40. https://doi.org/10.1016/S0140-6736(97)02250-2.
[12] Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A Randomized Trial of Pelvic Radiation Therapy Versus No Further Therapy in Selected Patients With Stage IB Carcinoma of the Cervix After Radical Hysterectomy and Pelvic Lymphadenectomy. Obstet Gynecol Surv 1999;54:571–3. https://doi.org/10.1097/00006254-199909000-00017.
[13] Portelance L, Chao KSC, Grigsby PW, Bennet H, Low D. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys 2001;51:261–6. https://doi.org/10.1016/S0360-3016(01)01664-9.
[14] Yang B, Zhu L, Cheng H, Li Q, Zhang Y, Zhao Y. Dosimetric comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy in patients with gynecologic malignancies: A systematic review and meta-analysis. Radiat Oncol 2012;7. https://doi.org/10.1186/1748-717X-7-197.
[15] Chen MF, Tseng CJ, Tseng CC, Yu CY, Wu C Te, Chen WC. Adjuvant concurrent chemoradiotherapy with intensity-modulated pelvic radiotherapy after surgery for high-risk, early stage cervical cancer patients. Cancer J 2008;14:200–6. https://doi.org/10.1097/PPO.0b013e318173a04b.
[16] Folkert MR, Shih KK, Abu-Rustum NR, Jewell E, Kollmeier MA, Makker V, et al. Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer. Gynecol Oncol 2013;128:288–93. https://doi.org/10.1016/j.ygyno.2012.11.012.
[17] Klopp AH, Moughan J, Portelance L, Miller BE, Salehpour MR, Hildebrandt E, et al. Hematologic toxicity in RTOG 0418: A phase 2 study of postoperative IMRT for gynecologic cancer. Int J Radiat Oncol Biol Phys 2013;86:83–90. https://doi.org/10.1016/j.ijrobp.2013.01.017.
[18] Viswanathan AN, Oncologist G, Miller BE, Biology T, Weidhaas J, Physics M, et al. RADIATION THERAPY ONCOLOGY GROUP RTOG 0921 A PHASE II STUDY OF POSTOPERATIVE INTENSITY MODULATED RADIATION THERAPY (IMRT) WITH CONCURRENT CISPLATIN AND BEVACIZUMAB FOLLOWED BY CARBOPLATIN AND PACLITAXEL FOR PATIENTS WITH ENDOMETRIAL CANCER Study Chairs Pr. 2011.
[19] Vandecasteele K, De Neve W, De Gersem W, Delrue L, Paelinck L, Makar A, et al. Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer : TTreatment planning, quality control, and clinical implementation. Strahlentherapie Und Onkol 2009;185:799–807. https://doi.org/10.1007/s00066-009-1986-8.
[20] Barillot I, Tavernier E, Peignaux K, Williaume D, Nickers P, Leblanc-Onfroy M, et al. Impact of post operative intensity modulated radiotherapy on acute gastro-intestinal toxicity for patients with endometrial cancer: Results of the phase II RTCMIENDOMETRE French multicentre trial. Radiother Oncol 2014;111:138–43. https://doi.org/10.1016/j.radonc.2014.01.018.
[21] Lim K, Small W, Portelance L, Creutzberg C, Jürgenliemk-Schulz IM, Mundt A, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Int J Radiat Oncol Biol Phys 2011;79:348–55. https://doi.org/10.1016/j.ijrobp.2009.10.075.
[22] Hasselle MD, Rose BS, Kochanski JD, Nath SK, Bafana R, Yashar CM, et al. Clinical outcomes of intensity-modulated pelvic radiation therapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2011;80:1436–45. https://doi.org/10.1016/j.ijrobp.2010.04.041.
[23] Peters WA, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606–13. https://doi.org/10.1200/JCO.2000.18.8.1606.
[24] Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2006;65:169–76. https://doi.org/10.1016/j.ijrobp.2005.10.019.
[25] Klopp A, Yeung A, Gil K, Wenzel L, Westin S, Konski A, et al. NRG Oncology RTOG 1203: a Randomized Phase III Study of Standard Vs . IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C). 2015.